
Sanofi, Regeneron Pharma secures USFDA approval for Dupixent for chronic spontaneous urticaria
Paris: Sanofi and Regeneron Pharma have received approval from the US Food and Drug Administration (FDA) for Dupixent (dupilumab) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) who remain …